Theragene Pharmaceuticals

Executive Summary

Theragene Pharmaceuticals is a San Diego-based biotechnology company founded in 2015, focused on developing novel treatments for cancer and cardiovascular diseases. The company leverages two core technology platforms: an immunotherapy platform for oncology and an Adeno-Associated Virus (AAV)-based gene therapy platform for cardiology. By combining cutting-edge science with efficient development and strategic collaborations, Theragene aims to address significant unmet medical needs in high-mortality disease areas. Its dual-platform approach positions it to capture value across both oncology and cardiology markets, which are expected to grow substantially over the next decade.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Oncology Immunotherapy Candidate60% success
• Q1 2027Phase I Interim Data for AAV-based Cardiology Gene Therapy40% success
• Q4 2026Strategic Partnership or Licensing Deal50% success